

**RED CELL GENOTYPING 2019: PATIENTS FIRST**  
**FRIDAY SEPTEMBER 20<sup>TH</sup>, 2019**  
**MASUR AUDITORIUM, CLINICAL CENTER, NIH BUILDING 10**  
**NATIONAL INSTITUTES OF HEALTH, 8600 ROCKVILLE PIKE, BETHESDA MD**

**PRELIMINARY PROGRAM**

**Session 1 – Scope of the Problem**

- Moderator** Willy A Flegel MD – NIH Clinical Center, Bethesda, MD  
8:25 – 8:30 Welcome and Warm-up (Willy A Flegel MD)  
8:30 – 8:45 Michael F Murphy, MD  
Title: *Keynote address: perspectives on red cell genotyping*  
8:45 – 9:20 Karin M Hoffmeister, MD – Blood Research Institute, Versiti  
Title: *Red blood cell glycomics*  
9:20 – 10:00 Christopher Tormey, MD – Yale University, New Haven, CT  
Title: *RBC genotype matching*  
10:00 – 10:30 Coffee Break

**Session 2 – Clinical Vignettes**

- Moderator** Charles D Bolan, MD – NIHLBI, Bethesda, MD  
10:30 – 10:50 Opal L-T Reddy, MD – NIH Clinical Center, Bethesda, MD  
Clinical Vignette I: *TBA*  
10:50 – 11:10 TBD  
Clinical Vignette II: *TBA*  
11:10 – 11:30 Marsha M Wheeler, PhD – BloodworksNW, Seattle, WA  
Clinical Vignette III: *Web-based analyses of novel red cell SNPs*  
11:30 – 12:30 Lunch Break

**Session 3 - Bench to Bedside**

- Moderator** Jerome L Gottschall, MD – Versiti, Milwaukee, WI  
12:30 – 1:10 Angelo D'Alessandro, MD – Biochemistry and Molecular Genetics, University of Colorado, Denver, CO  
Title: *Genome wide genotyping for transfusion medicine*  
1:10 – 1:40 Matthew Karafin, MD – Versiti, Milwaukee, WI  
Title: *Prevalence and risk factors for RBC alloantibodies (REDS-III)*  
1:40 – 2:15 Christine M Cserti-Gazdewich, MD – Department of Medicine, University of Toronto, Toronto, Canada  
Title: *Loss of RHD heterozygosity*  
2:15 – 2:30 Coffee Break

**Session 4 – Making It Happen**

- Moderator** Gregory A Denomme, PhD, FCSMLS(D) – Versiti, Milwaukee, WI  
2:30 – 3:15 John T Blake, PhD – Dalhousie University & Canadian Blood Services, Halifax, Canada  
Title: *Modeling rare blood in Canada*  
3:15 – 4:00 Fumiichiro Yamamoto, PhD, Dr HC  
Title: *How it all began in the 1980s: MN, ABO and Rh, and where we stand today*  
4:00 – 4:10 Discussion  
4:10 – 4:15 Closing Remarks and Evaluation